cardiac disorder News
-
Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries Asundexian is being evaluated as a potential improved treatment option in stroke prevention and could be part of an entirely new class of treatment options in thrombosis management that aims to uncouple efficacy from ...
By Bayer AG
-
NeuroSigma Continues to Build a Substantial Global Bioelectronics Patent Portfolio
NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing trigeminal nerve stimulation (TNS) technology to treat neurological and neuropsychiatric disorders, announced today that the following patents have issued or received notices of allowance in Canada and Japan: Canadian patent no. 2776694 entitled Devices, Systems, and Methods for Treatment of Neuropsychiatric ...
-
In-depth Mitochondrial Function Testing Services at Creative Biogene
New York, United States—April 21, 2022—Defects in mitochondrial function have long been suspected of contributing to the development of cancer. In this regard, Creative Biogene strives to explore mitochondrial functions that are yet to be discovered as well as the pathogenesis of mitochondria-associated cancers and possible interventions through in-depth mitochondrial function testing ...
-
Professor Gust H. Bardy, M.D. of Bardy Diagnostics Partners with Arrhythmia Alliance to Increase Patient Awareness of Heart Arrhythmias and Early Detection
(Seattle, WA – November 17, 2020) – Chief Medical Officer of Bardy Diagnostics and Clinical Professor of Medicine University of Washington Professor Gust H. Bardy sat down with Trudie Lobban, MBE, Founder and CEO of Arrhythmia Alliance, a non-profit organization dedicated to improving the diagnosis, treatment, and quality of life for all those affected by arrhythmias, to discuss the ...
-
New real world study data on reduced risk of adverse kidney outcomes for Xarelto compared to VKA
In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD), compared to vitamin K antagonists (VKA) XARENO evaluated the impact of Xarelto in patients with NVAF and CKD, given that ...
By Bayer AG
-
Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack involving up to 30,000 patients Bayer drives the development of its FXIa inhibitor, with the goal of offering a ...
By Bayer AG
-
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. The Alta study data, in patients with severe hemophilia A, are being presented today at the 63rd American ...
-
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
Implied total company value of up to USD 1 billion, inclusive of 40.8 percent stake currently held by Bayer Initial focus in neurology, cardiology, and immunology with start of first clinical program in Parkinson’s disease expected later this year BlueRock Therapeutics to continue to operate as an independent company Bayer AG and BlueRock Therapeutics today announced an agreement ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you